Shots:
- Zydus Lifesciences has entered into a strategic licensing, supply & commercialization agreement with Bioeq for Nufymco (ranibizumab), an interchangeable biosimilar to Lucentis, for the US market, marking an expansion of Zydus’ US biosimilar portfolio
- Under the agreement, Bioeq will handle development, manufacturing, registration & supply of the finished product while Zydus will lead US commercialization
- Nufymco is a VEGF inhibitor indicated for ophthalmic use which was given BLA approval by the US FDA on Dec 18, 2025
Ref: PR Newswire | Image: Zydus Lifesciences | Press Release
Related News: Formycon Partners with Zydus to Commercialize FYB206 (Biosimilar, Keytruda) in the US and Canada
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
